partners
They Trust Us
At PredictCan, we believe that transforming drug development requires more than one technology, it requires a shared vision.
Since our creation, we have built a growing network of international partners across the public and private sectors, bringing together biotechnology companies, academic institutions, hospitals, and research organizations.
What connects us is a common ambition: to develop more predictive and human-relevant approaches to drug development. Approaches that better anticipate drug efficacy and toxicity, account for individual patient variability, and ultimately contribute to delivering the right treatment to the right patient, while reducing reliance on animal testing.
By combining complementary expertise, technologies, and perspectives, our partnerships help accelerate the development and validation of more predictive, ethical, and accessible preclinical solutions.
Industry Partners
PredictCan partners with biotechnology companies to develop more predictive and human-relevant solutions for drug development. By combining our technology with our partners’ expertise, we aim to better predict drug efficacy and toxicity, account for human variability, and reduce reliance on animal testing. Together, we work to make preclinical drug development safer, faster, and more relevant to patients.
Public & Academic Partners
PredictCan collaborates with hospitals and clinical institutions to develop better tools for precision medicine and bring preclinical research closer to real patient biology. We also partner with leading universities and research institutions to advance science through a One Health approach, recognizing that human health is closely connected to our environment. Together, we aim to develop more predictive and human-relevant solutions for both medicine and environmental health.
Memberships
PredictCan is an active member of scientific and biotechnology organizations committed to advancing safer, more ethical, and more inclusive approaches to healthcare. By being part of these ecosystems, we engage with scientific experts, industry leaders, healthcare professionals, and regulators to exchange knowledge, challenge existing paradigms, and contribute to the transition toward more human-relevant and personalized medicine
